Initially the hs- CRP ( highly sensitive C-Reactive Protein ) test looked like another useful tool for helping my patients reduce their risk of developing cardiovascular disease.
I soon discovered that the test added more uncertainty to an already complex problem. Most of my patients were already taking medications known to reduce the levels of this inflammatory marker. I found it very difficult to explain a slightly elevated test result in a healthy, active patient with type 2 diabetes who did not smoke and was doing their best with exercise and weight control. The test could not separate the hidden inflammatory process in blood vessels from the residuals of a recent mild upper respiratory infection the week before.
I still believe the test is useful for helping us understand the disease process but is not useful in the clinical practice of medicine.
I have listed the common medications that have been shown to reduce this inflammatory marker
Aspirin has anti-inflammatory and anti platelet activity
Statins are primarily used to reduce LDL cholesterol and also have a potent rapid onset anti-inflammatory effect in blood vessels
CRP levels decline signficantly within 6 weeks of starting a Statin
Other studies have demonstrated a reduction in ischemic events with 16 weeks of starting a Statin
One study the AFCAOS/TEXCAPS primary prevention trial found lovastatin to be more effective
in people with elevated CRP levels .
Has anti -inflammatory effects especially when combined with aspirin.This drug is useful in acute
situations and in my experience was generally ordered and managed by a cardiologist .
ACE inhibitors may provide anti-inflammatory protection by suppressing these proinflammatory
People who stop smoking or lose weight have a decrease in inflammatory markers.
Exercise reduces inflammatory markers
Have fun , Be Smart and remember this good advise from my son -in-law Vinne
" if your not hungry enough to eat an apple , your not hungry"
David Calder, MD
- Nichol KL, Nordin J, Mullody J, et al. Influenza vaccination and reduction in hospitalization for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:13221332.
- Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650658.
- Smith JK, Dykes R, Douglas JE, et al. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999;281:17221727.
*Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:16151622.
*Circulation 1998;839844.Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvostatin on early recurrent ischemic events in acute coronary syndromes:
*The MIRACL study. A randomized controlled trial. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. JAMA 2001;285:17111718.
- Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672674.
- Vivekananthan DP, Bhatt DL, Chew DP, et al. Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-reactive protein. J Am Coll Cardiol 2003;41(Suppl A):10751165.
- Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:20362041.
- Moshfegh K, Rodondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after MI: Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36:699705.
- Yusuf S, Zhao F, Mehta SR, et al. The clopidogrel in unstable angina to prevent recurrent events trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494502.
- Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque stability. Circulation 2000;101:13721378.
- Hoshida S, Kato J, Nishino M, et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndromes. Circulation 2001;103:630633.
- Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998;98:800807.
- Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. SAVE Investigators. Circulation 1994;90:17311738.
- Acute Infarction Ramapril Efficacy (AIRE) Study Investigators. Effect of Ramapril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821828.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145153.